患有基础肺部疾病患者中 spp. 的分子特征及抗真菌药敏性

Molecular Characterization and Antifungal Susceptibility of spp. among Patients with Underlying Lung Diseases.

作者信息

Moglad Ehssan, Saeed Samar, Saeed Humodi, Ahmed Hind, Salih Kwathar, Altayb Hisham, Elhag Wafa

机构信息

Department of Pharmaceutics, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-Kharj P.O. Box 173, Saudi Arabia.

Department of Microbiology, Medicinal and Aromatic Plants and Traditional Medicine Research Institute (MAPTMRI), National Center for Research, Khartoum P.O. Box 2404, Sudan.

出版信息

Trop Med Infect Dis. 2022 Sep 28;7(10):274. doi: 10.3390/tropicalmed7100274.

DOI:10.3390/tropicalmed7100274

PMID:36288015

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9612272/

Abstract

BACKGROUND

Pulmonary aspergillosis is a lung infection caused by spp., which can cause severe illnesses in immunocompromised patients with underlying lung disease or who have asthma and inhale their spores. This study aimed to screen the antifungal susceptibility of spp. isolated from patients with underlying pulmonary infections and characterize the isolates using PCR and sequencing.

METHOD

Three hundred and eighty-four sputum or bronchoalveolar lavage samples were collected and processed for the isolation and identification, and characterization of species and molecular amplification of the ITS1-5.8S-ITS2 region by the PCR and Sanger sequencing method. Antifungal susceptibility tests for itraconazole and voriconazole were performed using the E-test.

RESULT

The overall results revealed that out of 384 patients, 32 (8.3%) were positive for fungal growth, including 28 (87.5%) spp. The highest resistance rate (100 and 44.4%) was obtained from itraconazole against and . In contrast, voriconazole revealed the best activities against all tested fungi compared to itraconazole. All were sensitive to voriconazole, while only 54.5% were sensitive to itraconazole. The MICs of E-test for spp were 1.6 ± 1.8 and 0.6 ± 0.93 for itraconazole and voriconazole, respectively.

CONCLUSIONS

The prevalence of aspergillosis was high, with a significant association with underlying lung diseases. Voriconazole was the drug of choice for isolated fungi.

摘要

背景

肺曲霉病是由曲霉属物种引起的肺部感染，可在患有基础肺部疾病的免疫功能低下患者或患有哮喘并吸入其孢子的患者中引发严重疾病。本研究旨在筛选从患有基础肺部感染的患者中分离出的曲霉属物种的抗真菌药敏性，并使用聚合酶链反应（PCR）和测序对分离株进行特征分析。

方法

收集384份痰液或支气管肺泡灌洗样本，进行处理以分离、鉴定曲霉属物种，并通过PCR和桑格测序法对ITS1-5.8S-ITS2区域进行分子扩增。使用E-test对伊曲康唑和伏立康唑进行抗真菌药敏试验。

结果

总体结果显示，在384例患者中，32例（8.3%）真菌生长呈阳性，其中28例（87.5%）为曲霉属物种。伊曲康唑对烟曲霉和黄曲霉的耐药率最高（分别为100%和44.4%）。相比之下，与伊曲康唑相比，伏立康唑对所有测试真菌显示出最佳活性。所有烟曲霉对伏立康唑敏感，而对伊曲康唑敏感的仅为54.5%。E-test对曲霉属物种的最低抑菌浓度（MIC），伊曲康唑为1.6±1.8，伏立康唑为0.6±0.93。